We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





iPLEX Pro High-Throughput, Low-Cost SARS-CoV-2 Panel Granted Emergency Use Authorization

By HospiMedica International staff writers
Posted on 19 Jun 2020
Print article
Image: The iPLEX Pro SARS-CoV-2 Panel (Photo courtesy of Agena Bioscience)
Image: The iPLEX Pro SARS-CoV-2 Panel (Photo courtesy of Agena Bioscience)
Agena Bioscience (San Diego, CA, USA), a global provider of low cost and high-throughput molecular testing solutions, has launched the iPLEX Pro SARS-CoV-2 Panel for qualitative detection of the novel coronavirus that causes COVID-19.

The single-reaction panel targets five regions of the viral genome, providing the accuracy and sensitivity required in the evolving landscape of SARS-CoV-2 testing. Clinical laboratories can process more than 6,000 samples each day running the assay on a single MassARRAY instrument, making it one of the highest throughput SARS-CoV-2 tests available under the US FDA's Emergency Use Authorization program. Priced at under $10 per sample, the panel makes large-scale testing more accessible. With the panel's release, Agena aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability.

"Agena is proud to offer a truly scalable platform to support the increasing demand for high-throughput SARS-CoV-2 testing," said Peter Dansky, CEO of Agena Bioscience. "To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. The MassARRAY System is the perfect tool for that."

"As the number of people being tested increases, panel sensitivity will be critical to ensuring proper patient management," said Dr. Darryl Irwin, Vice President of Scientific Affairs. "The iPLEX Pro SARS-CoV-2 Panel exhibits a limit of detection of 0.3 copies per uL. Labs can test large numbers of samples without sacrificing accuracy."

"The unique characteristics of the Agena detection technology provide significant supply chain advantages," said Jason Halsey, Senior Vice President of Technology and Operations. "Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers. Agena's iPLEX Pro SARS-CoV-2 kits and MassARRAY systems are ready for immediate deployment and we are equipped to supply millions of tests each month."

Related Links:
Agena Bioscience

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultra Low Floor Level Bed
Solite Pro

Print article

Channels

Surgical Techniques

view channel
Image: The device\'s LEDs light up in several colors, allowing surgeons to see which areas they need to operate on (Photo courtesy of UC San Diego)

Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons

During brain surgery, neurosurgeons need to identify and preserve regions responsible for critical functions while removing harmful tissue. Traditionally, neurosurgeons rely on a team of electrophysiologists,... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.